Chief Medical Officer Rock Edwin bought $78,824 worth of shares (305,000 units at $0.26), increasing direct ownership by 81% to 680,403 units (SEC Form 4)

$GLYC
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $GLYC alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Rock Edwin

(Last) (First) (Middle)
C/O GLYCOMIMETICS, INC
9708 MEDICAL CENTER DRIVE

(Street)
ROCKVILLE MD 20850

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
GLYCOMIMETICS INC [ GLYC ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Medical Officer
3. Date of Earliest Transaction (Month/Day/Year)
06/20/2024
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/20/2024 P 190,000 A $0.2532(1) 565,403 D
Common Stock 06/21/2024 P 115,000 A $0.2671(2) 680,403 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The Reporting Person purchased the securities on the open market at purchase prices ranging from $0.24 to $0.2594 per share, with a weighted average purchase price of $0.2532 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
2. The Reporting Person purchased the securities on the open market at purchase prices ranging from $0.2579 to $0.27 per share, with a weighted average purchase price of $0.2671 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
/s/ Brian F. Leaf, Attorney-in-Fact 06/24/2024
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $GLYC alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$GLYC

DatePrice TargetRatingAnalyst
3/21/2025Overweight
Cantor Fitzgerald
7/26/2024Buy → Hold
TD Cowen
12/22/2023$12.00Overweight
CapitalOne
11/12/2021$3.00 → $4.00Hold → Buy
Jefferies
More analyst ratings

$GLYC
Press Releases

Fastest customizable press release news feed in the world

See more
  • Crescent Biopharma to Present at the TD Cowen 45th Annual Health Care Conference

    WALTHAM, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent"), a private biotechnology company dedicated to advancing novel precision engineered molecules targeting validated biology to advance care for patients with solid tumors, announced management will present at the TD Cowen 45th Annual Health Care Conference on March 5, 2025, at 9:10 am ET. A live webcast of the presentation will be available at https://wsw.com/webcast/cowen177/cresc/2175696. An archived recording will be available for 90 days following the event. In October 2024, Crescent entered into an acquisition agreement with Rockville, Maryland-based GlycoMimetics, Inc. (NASDAQ:GLYC). Following

    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024

    Company to highlight lead program CR-001, a tetravalent VEGF1 x PD-1 bispecific antibody in development for treating solid tumors WALTHAM, Mass., Nov. 12, 2024 /PRNewswire/ -- Crescent Biopharma, Inc. ("Crescent"), a private biotechnology company dedicated to advancing novel precision engineered molecules targeting validated biology to advance care for patients with solid tumors, announced management will present at the Jefferies London Healthcare Conference on November 19, 2024, at 12:30 pm GMT/7:30 am EDT. A live webcast of the presentation will be available at https://wsw.c

    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting

    GlycoMimetics, Inc. (NASDAQ:GLYC) today announced that data from multiple clinical trials studying uproleselan in patients with acute myeloid leukemia (AML) have been accepted for presentation at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in San Diego, California, on December 7-10, 2024. ASH Annual Meeting abstracts may be accessed online at www.hematology.org. Details of GlycoMimetics presentations are as follows (all times PT): Publication Number: 733 Type: Oral Title: Efficacy and Safety of Uproleselan Combined with Chemotherapy Vs. Chemotherapy Alone in Relapsed/Refractory Acute Myeloid Leukemia: Findings from an International Phase 3 Tria

    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

$GLYC
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$GLYC
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$GLYC
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$GLYC
SEC Filings

See more

$GLYC
Leadership Updates

Live Leadership Updates

See more
  • GlycoMimetics Appoints Edwin Rock, M.D., Ph.D. as Chief Medical Officer

    GlycoMimetics, Inc. (NASDAQ:GLYC), a clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced that Edwin Rock, M.D., Ph.D. has joined the executive leadership team as Chief Medical Officer (CMO). Dr. Rock brings nearly two decades of biopharmaceutical clinical development experience, most recently serving as CMO for Partner Therapeutics, a privately-held commercial stage biotech based in Massachusetts. "We are thrilled to have Ed join the GlycoMimetics team. His proven biopharmaceutical leadership in the development and commercialization of novel hematologic therapies will be a significant asset as w

    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • GlycoMimetics Appoints Deepak Tiwari, Ph.D., as new Vice President, Technical Operations

    GlycoMimetics, Inc. (NASDAQ:GLYC) announced today that Dr. Deepak Tiwari has joined the Company as Vice President, Technical Operations. "Dr. Tiwari brings over 25 years of diverse CMC experience. He has contributed to more than 30 regulatory submissions and 15 commercial product launches throughout his career. As we continue to move uproleselan forward, Deepak's breadth of experience and leadership is a valuable addition to GlycoMimetics," commented Harout Semerjian, GlycoMimetics' Chief Executive Officer. Dr. Tiwari joins the Company from Rafael Pharmaceuticals where he was Vice President and Head of CMC Operations working on development of devimistat in multiple indications including p

    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • GlycoMimetics Appoints Bruce Johnson Senior Vice President and Chief Commercial Officer

    GlycoMimetics, Inc. (NASDAQ:GLYC) announced today that Bruce Johnson has joined its executive leadership team as Senior Vice President and Chief Commercial Officer. "Bruce brings to GlycoMimetics a wealth of oncology / hematology expertise particularly in leading commercial and development activities across multiple launches. He shepherded two AML drugs, Midostaurin and Venetoclax, through late-stage development and approval, uniquely qualifying him to lead the commercialization efforts of our lead asset, uproleselan, should the results of our ongoing Phase 3 registrational AML trial prove positive. His near-term focus will be to develop a commercialization strategy for uproleselan, accele

    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

$GLYC
Financials

Live finance-specific insights

See more
  • GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma

    Following closing, the combined company will advance Crescent's portfolio of precision-engineered biologics to improve outcomes for patients with solid tumors Crescent's lead program CR-001, a tetravalent PD-1 x VEGF bispecific antibody incorporating the cooperative binding mechanism underpinning recent immuno-oncology breakthrough, expected to have preliminary proof of concept data in 2H26 Crescent pipeline also includes two novel antibody-drug conjugates with topoisomerase inhibitor payloads, CR-002 and CR-003 Concurrent financing of approximately $200 million anticipated to fund operations through 2027 Companies to hold a conference call on Tuesday October 29, at 8:00am EDT GlycoMim

    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

    Company exploring path forward for uproleselan in multiple AML settings based on observed efficacy results, including clinically meaningful results in primary refractory AML, and significant unmet patient need Uproleselan demonstrated a clinically meaningful improvement in median overall survival (mOS) for patients with primary refractory AML; mOS was 31.2 months for the uproleselan arm compared to 10.1 months for the placebo arm in this subgroup Adverse events for uproleselan were consistent with known side effect profiles of chemotherapy used in the study Advancing discussions with the National Cancer Institute (NCI) and the Alliance for Clinical Trials in Oncology for Phase 2/3

    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

    Study of uproleselan combined with chemotherapy did not meet its primary endpoint of overall survival in the intent to treat population Adverse events were consistent with known side effect profiles of chemotherapy used in the study Comprehensive data analysis with medical, statistical, and regulatory experts underway and will be shared as appropriate; company will submit results for presentation at an upcoming medical meeting National Cancer Institute (NCI) Phase 2/3 study in newly diagnosed AML patients remains ongoing Conference call and webcast to be hosted today, May 6, 2024, at 8:30 a.m. ET. GlycoMimetics, Inc. (NASDAQ:GLYC), a late clinical-stage biotechnology company

    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

$GLYC
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more

$GLYC
Insider purchases explained

Analytical look into recent insider purchases

See more
  • What Does the Recent Purchase at GlycoMimetics Inc. on Jun 20 Indicate?

    Recently, on June 20, 2024, an insider purchase was made at GlycoMimetics Inc., grabbing the attention of investors. According to the SEC Form 4 filing, SVP Finance, CFO Hahn Brian M. bought $4,335 worth of shares (17,500 units at $0.25), boosting direct ownership by 33% to 70,643 units. Insider transactions are closely monitored by investors as they can provide insights into the company's prospects and the confidence of insiders in the business. Let's delve deeper into the recent insider purchase and analyze any potential patterns or significance in comparison to other insider transactions at GlycoMimetics Inc. In early April 2024, Goldberg Mark Alan was granted 4,584 shares, augmenting di

    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care